JTO Clinical and Research Reports (Feb 2021)

A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib

  • Min Zhang, MBBS,
  • Huan Zhou, MM,
  • Dan Liu, MD, PhD,
  • Ruoying Yu, MD, PhD,
  • Jun Chen, MD, PhD

Journal volume & issue
Vol. 2, no. 2
p. 100106

Abstract

Read online

Most patients with NSCLC, initially sensitive, will develop resistance after a period of time after the application of ALK inhibitors. We present here a rare LOC285000-ALK-NCK2 gene fusion with response to crizotinib treatment; the patient achieved a progression-free survival of 23 months.

Keywords